These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 21388824)
1. Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Goffredo V; Paradiso A; Ranieri G; Gadaleta CD Crit Rev Oncol Hematol; 2011 Dec; 80(3):393-410. PubMed ID: 21388824 [TBL] [Abstract][Full Text] [Related]
2. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059 [TBL] [Abstract][Full Text] [Related]
3. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Marcus R Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024 [TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
5. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
7. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Meredith RF Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435 [TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions. Minocha J; Salem R; Lewandowski RJ Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288 [TBL] [Abstract][Full Text] [Related]
9. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment]. de Nully Brown P; Jurlander J; Lindén O; Hansen M Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425 [TBL] [Abstract][Full Text] [Related]
11. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Leonard JP; Siegel JA; Goldsmith SJ Cancer Invest; 2003 Apr; 21(2):241-52. PubMed ID: 12743990 [TBL] [Abstract][Full Text] [Related]
16. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS J Comp Eff Res; 2013 Jul; 2(4):435-44. PubMed ID: 24236684 [TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. Macklis RM Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564 [TBL] [Abstract][Full Text] [Related]